drugset / Trial / NCT03646461
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, randomized, phase II trial to test the efficacy of Ibrutinib in combination with either Nivolumab or Cetuximab in the treatment of recurrent and/or metastatic head an neck squamous cell carcinoma
Timeline
- Start
- 2018-10-17
- Primary completion
- 2020-08-15
- Completion
- 2021-05-13
Outcome
Outcome not reported
Stopped: “Lack of scientific process of cancer-related clinical intervention”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Ibrutinib | Small molecule | 560 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |